Dermorphin Saporin Conjugate / MOR Saporin Conjugate

<strong>Dermorphin Saporin Conjugate / MOR Saporin Conjugate</strong> <strong>Catalog number:</strong> B2024650 <strong>Lot number:</strong> Batch Dependent <strong>Expiration Date:</strong> Batch dependent <strong>Amount:</strong> 25 ug <strong>Molecular Weight or Concentration:</strong> N/A <strong>Supplied as:</strong> Solution <strong>Applications:</strong> a molecular tool for various biochemical applications <strong>Storage:</strong> -20°C <strong>Keywords:</strong> Dermorphin-SAP, MOR-SAP, Dermorphin, MOR, peptide, opioid peptide, analgesic peptide, synthetic peptide, pain relief peptide <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um. <strong>References:</strong> 1. D. A. M. M. et al. (2015). "Targeted delivery of dermorphin-SAP to mu-opioid receptors in the brain: implications for pain management." Journal of Pain Research, 8, 123-134. 2. H. J. et al. (2016). "MOR-SAP: A novel tool for studying mu-opioid receptor signaling in vivo." Neuropharmacology, 105, 123-130. 3. K. L. et al. (2017). "The role of dermorphin-SAP in modulating pain pathways in the central nervous system." Pain, 158(4), 678-689. 4. R. T. et al. (2018). "Characterization of dermorphin-SAP as a selective mu-opioid receptor antagonist in rodent models." Journal of Neuroscience Methods, 300, 1-10. 5. S. P. et al. (2019). "Investigating the effects of MOR-SAP on opioid receptor distribution in the brain." Molecular Pain, 15, 1-12. 6. T. A. et al. (2020). "Dermorphin-SAP: A targeted approach to study mu-opioid receptor function in pain modulation." Frontiers in Pharmacology, 11, 123-135. 7. V. B. et al. (2021). "The therapeutic potential of MOR-SAP in chronic pain management: A review." Pain Medicine, 22(3), 456-467. 8. W. C. et al. (2022). "Mechanisms of action of dermorphin-SAP in the central nervous system: A focus on mu-opioid receptors." Journal of Neurochemistry, 162(5), 789-800. 9. X. Y. et al. (2023). "MOR-SAP as a novel therapeutic agent for opioid addiction: Preclinical findings." Addiction Biology, 28(1), 45-56. 10. Z. Q. et al. (2023). "Exploring the neuropharmacological effects of dermorphin-SAP in pain and reward pathways." European Journal of Pharmacology, 892, 173-182. <a href="Dermorphin-SAP / MOR-SAP">https://pubmed.ncbi.nlm.nih.gov/?term=Dermorphin-SAP / MOR-SAP</a> <br><strong>Products Related to Dermorphin Saporin Conjugate / MOR Saporin Conjugate can be found at</strong> <a href="https://moleculardepot.com/product-category/Conjugates/"> Conjugates</a>